- Recruiting
NCT04405167: Phase 1: Tasquinimod for the Treatment of Relapsed or Refractory Myeloma
NCT04405167: Phase 1: Tasquinimod for the Treatment of Relapsed or Refractory Myeloma
NCT04405167: Phase 1: Tasquinimod for the Treatment of Relapsed or Refractory Myeloma
This study is the first study of tasquinimod, an inhibitor of S100A9, in patients with multiple myeloma.
Sponsor
Collaborator
ClinicalTrials.gov Identifier: NCT04405167
Official Title: Phase 1 Study of Tasquinimod Alone and in Combination With Standard Therapy for Relapsed or Refractory Myeloma
First Posted : May 28, 2020
Click here to see details on ClinicalTrials.gov
Drug: Tasquinimod
Drug: IRd chemotherapy with ixazomib, lenalidomide, and dexamethasone
Tasquinimod (Code C74080)
ABR-215050
TASQ
Tasquinimod
TASQUINIMOD
Location
United States, Pennsylvania